Abstract | OBJECTIVE: ANIMALS: 2,529 weaned crossbred beef calves. PROCEDURES: At each of 2 feedlots, calves at risk of developing BRDC were administered a single dose of gamithromycin (6.0 mg/kg, SC; n = 1,263) or tulathromycin (2.5 mg/kg, SC; 1,266) metaphylactically. Health (BRDC morbidity, mortality, case-fatality, and retreatment rates) and performance (average daily gain, dry matter intake, and feed-to-gain ratio) outcomes were compared between treatments via classical hypothesis testing. Bioequivalence limits for gamithromycin and tulathromycin were established for outcomes for which no significant difference between treatments was detected. RESULTS: Mean BRDC morbidity rate (31.0%) for calves administered gamithromycin was greater than that (22.9%) for calves administered tulathromycin; otherwise, health and performance did not differ between treatments. Limits for mean differences within which gamithromycin was considered bioequivalent to tulathromycin were ± 10% for BRDC retreatment rate, ± 3.5% for BRDC mortality rate, ± 16% for case-fatality rate, ± 37 kg for final body weight, ± 0.1 kg/d for average daily gain, ± 0.3 kg/d for dry matter intake, and ± 0.7 for feed-to-gain ratio. CONCLUSIONS AND CLINICAL RELEVANCE:
|
Authors | Siddartha Torres, Dan U Thomson, Nora M Bello, Bruce J Nosky, Chris D Reinhardt |
Journal | American journal of veterinary research
(Am J Vet Res)
Vol. 74
Issue 6
Pg. 839-46
(Jun 2013)
ISSN: 1943-5681 [Electronic] United States |
PMID | 23718651
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Disaccharides
- Heterocyclic Compounds
- Macrolides
- tulathromycin
- gamithromycin
|
Topics |
- Animals
- Anti-Bacterial Agents
(pharmacology)
- Bovine Respiratory Disease Complex
(prevention & control)
- Cattle
- Disaccharides
(pharmacology)
- Heterocyclic Compounds
(pharmacology)
- Housing, Animal
- Macrolides
(pharmacology)
- Male
- Risk Factors
|